The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.

Clin Rheumatol 2019 Mar 6;38(3):949-954. Epub 2018 Nov 6.

Immuno-Rheumatology Group, Hospital La Paz Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain.

To investigate the effect of concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with adalimumab or infliximab on maintaining serum drug and clinical outcomes after the first year of treatment in patients with rheumatoid arthritis (RA). Second, to assess the influence of methotrexate (MTX) dose on these outcomes. Ninety-two patients with RA starting infliximab (n = 67) or adalimumab (n = 25) tumor necrosis factor inhibitor (TNFi) with available drug levels and clinical improvement assessment (European League Against Rheumatism [EULAR] response) after 12 months were included. Patients were grouped according to concomitant csDMARD use: (i) TNFi monotherapy; (ii) TNFi+MTX; (iii) TNFi with csDMARDs other than MTX (TNFi+OD). Patients receiving MTX were also classified by dose as < 15 mg/week (TNFi+MTX<15) and ≥ 15 mg/week (TNFi+MTX≥15). Logistic regression analyses were employed. More TNFi+MTX patients had circulating serum TNFi at 12 months (71% TNFi+MTX vs. 20% TNFi+OD vs. 9% TNFi monotherapy). Of these, the probability of maintaining serum TNFi levels was twice (OR 2.3; p = 0.06) than that of patients without MTX. However, statistically significant results were observed only for the highest MTX dose (OR 4.9; p = 0.02). Most patients achieving good EULAR response were treated with TNFi+MTX (81%). The probability of achieving this response was three times higher in patients within the TNFi+MTX group (OR 3.4; p = 0.03); however, no differences were found with regard to MTX dose. The persistence of serum TNFi and the probability of achieving clinical response are influenced by MTX but not by OD in patients with RA treated with infliximab or adalimumab.

Download full-text PDF

Source
http://link.springer.com/10.1007/s10067-018-4355-0
Publisher Site
http://dx.doi.org/10.1007/s10067-018-4355-0DOI Listing
March 2019
27 Reads

Publication Analysis

Top Keywords

levels clinical
8
rheumatoid arthritis
8
drug levels
8
serum drug
8
anti-rheumatic drugs
8
disease-modifying anti-rheumatic
8
necrosis factor
8
patients rheumatoid
8
tumor necrosis
8
patients
5
n = 25 tumor
4
adalimumab n = 25
4
inhibitor tnfi
4
improvement assessment
4
assessment european
4
clinical improvement
4
tnfi drug
4
n = 67 adalimumab
4
factor inhibitor
4
patients starting
4

References

(Supplied by CrossRef)

EH Vogelzang et al.
Ann Rheum Dis 2015

D Ternant et al.
Br J Clin Pharmacol 2014

JS Smolen et al.
Ann Rheum Dis 2017

MA Martín-martínez et al.
Reumatol Clin 2017

MF Pouw et al.
Ann Rheum Dis 2015

AM Gestel van et al.
Arthritis Rheum 1996

D Pascual-Salcedo et al.
Rheumatology 2011

GM Bartelds et al.
Ann Rheum Dis 2007

RN Maini et al.
Arthritis Rheum 1998

Similar Publications